Results for tag: "Strensiq"

Strensiq is a drug used to treat endocrine and metabolic disorders. It is a recombinant form of human lysosomal acid lipase (LAL) enzyme, which is used to treat lysosomal acid lipase deficiency (LAL-D). This rare genetic disorder is characterized by the accumulation of lipids in the lysosomes of cells, leading to organ damage and other serious complications. Strensiq is administered as a subcutaneous injection and works by replacing the missing enzyme, allowing the body to break down and metabolize lipids. The Strensiq market is composed of pharmaceutical companies that develop, manufacture, and market the drug. These companies include Alexion Pharmaceuticals, Inc., Pfizer, Inc., and Sanofi Genzyme. Show Less Read more